对阿尔茨海默氏症激发的新视角:潜在的范式转变
1Centre for Rare Diseases, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, DK-8200 Aarhus, Denmark.
International journal of molecular sciences
|April 17, 2025
概括
痴呆症中的激动可能源于自主神经系统失衡. 研究表明,在激动期间出现了副交感性撤退和同情性过度活跃,这暗示了新的治疗可能性.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 自主神经病学 自主神经病学
背景情况:
- 兴奋是痴呆症中普遍存在且具有挑战性的神经精神病症状.
- 最近的研究表明,兴奋和自主神经系统之间存在联系.
- 有限的研究存在于自主功能在激动情节期间.
研究的目的:
- 调查自主神经系统活动与痴呆症激动之间的关联.
- 探索基于自主功能激发的潜在治疗点.
主要方法:
- 审查关于痴呆症中自主功能和激动现象的现有文献.
- 分析了两个涉及血管痴呆症,阿尔茨海默氏症痴呆症和CLN3相关痴呆症患者的病例系列.
- 在激动状态下测量自主系统参数.
主要成果:
- 这两种病例系列都表明在激动行为期间出现了副交感性戒断和同情性过度活跃.
- 这些自主性变化在与激动情节的时间附近观察到.
结论:
- 这些发现表明,在患有激动症的患者中,可能存在与时间相关的自主失衡.
- 在一个更大的阿尔茨海默氏症队列中证明这种不平衡可能会验证通过皮肤的阴道刺激作为一种新的激发治疗方法.
相关概念视频
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Alzheimer's Disease: Overview
317
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
317
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85
Parkinson's Disease: Treatment
152
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
152
Parkinson's Disease: Overview
311
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
311
Dementia
68
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
68


